From Cure Today:
Across the fields of renal cell carcinoma (RCC), bladder cancer and prostate cancer, immunotherapy agents are moving through the pipeline and impacting patient outcomes—some quicker than others. “Now, we see that anti–PD-1 therapy has taken off,” explains Randy F. Sweis. “Suddenly, GU has come at the forefront of immunotherapy again and we are all excited about that.”
Read the full story.